Insider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Sells $43,260.00 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $7.21, for a total value of $43,260.00. Following the completion of the sale, the chief operating officer now owns 535,457 shares in the company, valued at $3,860,644.97. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Tina Marriott also recently made the following trade(s):

• On Thursday, May 30th, Tina Marriott sold 3,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.78, for a total transaction of $26,340.00.
• On Thursday, April 25th, Tina Marriott sold 3,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.67, for a total transaction of $23,010.00.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX opened at $7.50 on Monday. The firm has a market cap of $1.78 billion, a PE ratio of -4.69 and a beta of 0.86. Recursion Pharmaceuticals, Inc. has a twelve month low of $4.97 and a twelve month high of $16.75. The firm’s 50 day moving average price is $8.84 and its 200 day moving average price is $9.95.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.04. Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. The company had revenue of $13.80 million for the quarter, compared to the consensus estimate of $11.10 million. During the same period last year, the business posted ($0.34) earnings per share. The firm’s revenue was up 14.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.6 earnings per share for the current fiscal year.

Institutional Trading of Recursion Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Benjamin F. Edwards & Company Inc. bought a new stake in shares of Recursion Pharmaceuticals in the 1st quarter worth about $26,000. National Bank of Canada FI boosted its holdings in shares of Recursion Pharmaceuticals by 90.9% in the 4th quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock worth $31,000 after acquiring an additional 1,500 shares in the last quarter. First Horizon Advisors Inc. acquired a new stake in Recursion Pharmaceuticals during the 4th quarter valued at $47,000. Oxford Wealth Group LLC acquired a new position in Recursion Pharmaceuticals in the first quarter worth $106,000. Finally, Daiwa Securities Group Inc. grew its holdings in shares of Recursion Pharmaceuticals by 1,508.6% during the fourth quarter. Daiwa Securities Group Inc. now owns 11,759 shares of the company’s stock worth $116,000 after purchasing an additional 11,028 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on RXRX. KeyCorp upped their target price on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Monday, March 4th. Needham & Company LLC reissued a “buy” rating and set a $17.00 target price on shares of Recursion Pharmaceuticals in a research note on Tuesday, June 25th.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.